0.186 -0.141 (-43.1%) | 03-28 16:00 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 0.35 | 1-year : | 0.45 |
Resists | First : | 0.3 | Second : | 0.38 |
Pivot price | 0.32 | |||
Supports | First : | 0.16 | Second : | 0.13 |
MAs | MA(5) : | 0.3 | MA(20) : | 0.33 |
MA(100) : | 0.38 | MA(250) : | 1.09 | |
MACD | MACD : | -0.1 | Signal : | -0.1 |
%K %D | K(14,3) : | 15.1 | D(3) : | 19.6 |
RSI | RSI(14): 23 | |||
52-week | High : | 4 | Low : | 0.16 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ TNXP ] has closed below the lower bollinger band by 37.8%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ TNXP ] is to continue within current trading range. Bollinger Bands are 11.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 0.34 - 0.35 | 0.35 - 0.35 |
Low: | 0.16 - 0.17 | 0.17 - 0.17 |
Close: | 0.18 - 0.19 | 0.19 - 0.19 |
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The company's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer, including TNX-1500, a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. Its rare disease portfolio comprises TNX-2900 for the treatment of Prader-Willi syndrome. The company's infectious disease pipeline includes TNX-801, a vaccine to prevent smallpox and monkeypox; TNX-1840 and TNX-1850 that are live virus vaccines based on its recombinant pox vaccine (RPV) platform for COVID-19; TNX-3500, a small molecule antiviral drug to treat acute COVID-19; and TNX-102 SL, a small molecule drug to treat Long COVID, a chronic post-acute COVID-19 condition. Its CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions, including TNX-102 SL, which is in mid-Phase 3 development for the management of fibromyalgia; TNX-1900 that is in development for the prevention of migraine headache; and TNX-1300, a biologic designed to treat cocaine intoxication. The company was founded in 2007 and is headquartered in Chatham, New Jersey.
Thu, 28 Mar 2024
U.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.12% - MSN
Thu, 28 Mar 2024
Why Tonix Pharmaceuticals Stock (TNXP) Is Getting Obliterated - Tonix Pharmaceuticals (NASDAQ:TNXP) - Benzinga
Thu, 28 Mar 2024
Tonix Pharmaceuticals Announces Pricing of $4.4 Million Registered Direct Offering - GlobeNewswire
Tue, 26 Mar 2024
Tonix Pharma Earns FDA Pediatric Designation Amid Risks - TipRanks.com - TipRanks
Tue, 26 Mar 2024
Tonix Pharmaceuticals (NASDAQ:TNXP) Receives New Coverage from Analysts at StockNews.com - Defense World
Mon, 25 Mar 2024
Tonix's TNX-2900 gains FDA rare pediatric disease tag By Investing.com - Investing.com
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 59 (M) |
Shares Float | 21 (M) |
Held by Insiders | 0 (%) |
Held by Institutions | 28.6 (%) |
Shares Short | 616 (K) |
Shares Short P.Month | 638 (K) |
EPS | -9.27 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 6.8 |
Profit Margin | 0 % |
Operating Margin | -705.7 % |
Return on Assets (ttm) | -40.6 % |
Return on Equity (ttm) | -69.2 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0.06 |
EBITDA (p.s.) | -2.05 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -102 (M) |
Levered Free Cash Flow | -84 (M) |
PE Ratio | -0.03 |
PEG Ratio | 0 |
Price to Book value | 0.02 |
Price to Sales | 2.73 |
Price to Cash Flow | -0.11 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |